Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 11Active not recruiting 5Terminated 4Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Small Cell Lung Carcinoma 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma 2Liver Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Bile Duct Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Resectable Biliary Tract Cancer 1Radiation Pneumonitis 1

Interventions

Paclitaxel 35Carboplatin 35Bevacizumab 14olaparib 13niraparib 11apatinib 11Gemcitabine 10liposomal doxorubicin 9Hyperthermic Intraperitoneal Chemotherapy 9Cisplatin 9pembrolizumab 8Cyclophosphamide 8fludarabine 7Etoposide 7Topotecan 6fluzoparib 5Surveys and Questionnaires 5Drug Therapy 5Albumin-Bound Paclitaxel 5anlotinib 4Immunohistochemistry 4Ifosfamide 4Doxorubicin 4Docetaxel 4Cytoreduction Surgical Procedures 4Taxes 3Surgical Procedures, Operative 3Poly(ADP-ribose) Polymerase Inhibitors 3Neoadjuvant Therapy 3Laparoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasms × durvalumab × Clear all
NCT03283943 2018-07-11

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

British Columbia Cancer Agency

Phase 1 Unknown
22 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡